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Study protocol PRevalence of Abuse and Intimate Partner Violence 
Surgical Evaluation (P.R.A.I.S.E.): rationale and 
design of a multi-center cross-sectional study. 
PRAISE Investigators
Abstract
Background: Intimate partner violence (IPV) is described by the American Medical Association as "a pattern of 
coercive behaviors that may include repeated battering and injury, psychological abuse, sexual assault, progressive 
social isolation, deprivation, and intimidation." The long-term consequences of IPV include health risks, posttraumatic 
stress disorder, depression, and staggering economic costs for health care of victims. Intimate partner violence is often 
underreported among women who seek medical attention. The current study seeks to address the issue of possible 
underreporting of IPV in orthopaedic fracture clinics by establishing prevalence rates of IPV among women seeking 
treatment for musculoskeletal injuries.
Methods/Design: We propose a cross-sectional multicenter study wherein 3,600 women will complete a self-reported 
written questionnaire across clinical sites in North America, Europe, and Australia. Recruitment of participants will take 
place at orthopaedic fracture clinics at each clinical site. The questionnaire will contain a validated set of questions 
used to screen for IPV, as well as questions that pertain to the participant's demographic, injury characteristics, and 
experiences with health care utilization. Female patients presenting to the orthopaedic fracture clinics will complete 
two validated self-reported written questionnaires (Woman Abuse Screening Tool (WAST) and the Partner Violence 
Screen (PVS)) to determine the prevalence of IPV in the past 12 months and in their lifetime. The two questionnaires 
were designed for rapid assessment of IPV status in emergency departments, family practice, and women's health 
clinics that we believe are similar to our intended setting of an orthopaedic clinic.
Discussion: If the prevalence of IPV among women attending orthopaedic clinics is greater than the current 
perceptions of orthopaedic surgeons, this study will serve to advocate for the continued education of medical 
professionals to better recognize probable IPV cases and offer existing services to enhance the care of these patients.
Background
Intimate partner violence (IPV) is described by the
American Medical Association as "a pattern of coercive
behaviors that may include repeated battering and injury,
psychological abuse, sexual assault, progressive social iso-
lation, deprivation, and intimidation" [1]. The long-term
consequences of IPV include health risks, posttraumatic
stress disorder, depression, and staggering economic
costs for health care of victims [2].
The cumulative lifetime prevalence of domestic vio-
lence for women admitted to the Emergency Department
is approximately 54 percent [2]. However, IPV is underre-
ported among women who seek medical attention [2-4].
The American College of Surgeons position statement on
IPV states that surgeons have the responsibility to iden-
tify IPV and appropriately treat women at risk of further
harm [5]. In July 2009, the Canadian Orthopaedic Associ-
ation (COA) released a position on the role of the ortho-
p a e d i c  s u r g e o n  i n  t h e  c a r e  o f  a b u s e d  w o m e n .  T h e
statement affirms that the "COA recognizes that IPV is a
significant social determinant of morbidity and mortality,
and that orthopaedic surgeons are well positioned to
identify patients living with IPV and initiate an interven-
tion. Therefore, the COA encourages its members to edu-
cate themselves further about IPV and considers it good
medical practice to take steps to identify and offer assis-
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tance to its victims" [6]. In accordance with this position
statement, the COA is working towards raising awareness
of domestic violence as well as educating orthopaedic
surgeons over the next year. This shows the timeliness of
the issue in orthopaedic surgery.
Despite these positive initiatives, there is currently no
data in orthopaedic literature to support the hypothesis
that the prevalence of IPV in orthopaedic trauma clinics
warrants additional resources to identify and manage vic-
tims [7,8]. The current study seeks to address the concern
that IPV is underreported in orthopaedic fracture clinics
by establishing prevalence rates of IPV among women
seeking treatment for musculoskeletal injuries across
multiple centers in different jurisdictions. This will be the
first multi-center study to evaluate this critical issue in
the field of orthopaedic trauma.
The proportion of women in Canada 15 years of age
and older who have experienced physical or sexual vio-
lence in a marital or common-law union in the last 5
years is between 6 percent and 8 percent, affecting
approximately 300,000 women in the province of Ontario
[9]. This is likely an underreporting of the true rate since
detection is hindered by the reluctance of respondents to
talk openly about their IPV experience [10]. In docu-
mented cases of IPV in Canada, 25 percent of women
reported that they were beaten, 20 percent reported
choking, and 20 percent were sexually assaulted. Of the
documented cases, 40 percent of women in Canada who
have experienced IPV suffer a physical injury, and 15 per-
cent of these cases are serious enough to warrant medical
attention [10].
Several studies have found that IPV is underreported
among women who seek medical attention [2-4]. Dear-
water et al. noted that women who were treated at 11
community hospital emergency departments secondary
to IPV-related acute trauma were identified in only 44
percent of all cases presented [3]. Davis et al. reported
that of the victims who presented to a level I trauma cen-
ter because of confirmed or probable IPV, only 26 percent
received referrals to social services and 63 percent were
discharged without any investigation into their safety at
home [11]. The investigators further note that the num-
ber of IPV victims was underestimated because of the
propensity of conflicting information in the patients' his-
tory, lack of information to adequately rule out IPV, and
failing to actively screen for IPV among all cases who pre-
sented to their trauma service. Additionally, a recent
study found that sprains, dislocations, fractures, and foot
injuries accounted for 28 percent of all clinical manifesta-
tions of IPV among women who were identified in a 2-
year period by the Minnesota Domestic Abuse Program
[12]. Despite these findings, IPV remains underempha-
sized in this medical field [7].
The majority of orthopaedic surgeons (87%), however,
in a Canada-wide survey believed that female victims of
IPV accounted for less than 1 percent of patients in their
care [7]. The findings of this survey suggested a misper-
ception between surgeons' beliefs about the prevalence of
IPV in their fracture clinics and reported rates of IPV in
the community [7]. Current guidelines suggest that
orthopaedic surgeons should pla y an active role in the
identification of IPV victims and their timely referral to
local agencies [7,13,14].
To explore prevalence rates of IPV in the fracture clinic
setting, we conducted a pilot screening study of injured
women across two trauma centers in Ontario. We found
that one third of women have been victims of IPV
(including physical, emotional, and sexual abuse) in the
past 12 months. Furthermore, we found that 2.5 percent
of women presented with injuries directly resulting from
IPV [15]. While our findings were compelling, the gener-
alizability between two level I trauma centers remained
unknown. The current proposal aims to expand the gen-
eralizability and significantly increase the sample size to
provide more precise estimates of IPV in the fracture
clinic setting.
Research Objectives and Hypotheses
The primary objective of this observational study is to
determine the proportion of women who have experi-
enced IPV in the past 12-months among women who
present to orthopaedic fracture clinics for treatment of
orthopaedic injuries. We define IPV as physical, emo-
tional, or sexual abuse that is caused by an intimate part-
ner such as a victim's spouse, common-law partner, or
dating partner.
Secondary objectives include determining the propor-
tion of women presenting to orthopaedic fracture clinics
for the treatment of orthopaedic injuries who have expe-
rienced IPV in their lifetime; determining the proportion
of women who present to orthopaedic clinics for treat-
ment of orthopaedic injuries that present with an ortho-
paedic injury that was the direct result from IPV from a
current and ongoing relationship; and investigating
patients' previous experiences, knowledge, and percep-
tions with regards to approaching healthcare profession-
als about IPV.
We hypothesize that the prevalence of IPV among
women who present to orthopaedic fracture clinics for
treatment of orthopaedic injuries is sufficiently high to
warrant targeted programs to assist orthopaedic surgeons
in the clinic with identification and appropriate referral to
specialists.
Methods/Design
We propose a cross-sectional multi-center study wherein
3,600 women will complete a validated self-reported  BMC Musculoskeletal Disorders 2010, 11:77
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written questionnaire across ten clinical sites in North
America, Europe, and Australia. Recruitment of partici-
pants will take place at the fracture clinic at each clinical
site. The questionnaires will contain a validated set of
questions used to screen for IPV, as well as questions that
pertain to the participant's demographic, fracture charac-
teristics, and experiences with health care utilization. A
flow diagram of the study is presented in Figure 1.
Rationale for an Observational Study Design
We explored the possibility of addressing our research
questions by other less costly or less time-consuming
study designs. Other methods considered were a retro-
spective cohort and a cross-sectional study using a self-
reported written questionnaire sent by mail. The advan-
tages and disadvantages of these study designs when
compared to the proposed design are discussed below.
A retrospective cohort study would be less costly and
time consuming than the prospective cohort study or
case-control study proposed. A medical chart review can
be undertaken at each participating clinic, where data
collectors can review the charts for reported cases of IPV
among patients who visited the clinic within a certain
time period. Such a study would have a greater likelihood
of undergoing an expedited ethics review than a study
that requires active participation from the respondent.
However, given that IPV is not properly recognized
among health professionals [3,4,16], such a review would
likely be unable to detect a significant proportion of IPV
victims. Moreover, the non-standardization of the defini-
tion of IPV may also affect the internal validity of the
study and result in an over reporting or underreporting of
cases of IPV.
The use of a mailed questionnaire that can be com-
pleted and sent back by the participant is a potential
strategy that would save costs over a study that requires
the respondent to be present at the clinic to be enrolled.
Female patients over the age of 18 years can be identified
from the registries of the orthopaedic fracture and injury
clinics and be mailed a written questionnaire and infor-
mation letter about the study. Informed consent would be
implied if the questionnaire is sent back to the study
investigators. However, while such a study would be eas-
ier to implement than a prospective study, the adminis-
tration of a mailed questionnaire has been met with
limited success. In their study of abuse prevalence among
patients visiting gynaecology clinics, Wijma et al. noted
response rates as low as 67 percent among recruiting
Figure 1 Study Flow diagram.  BMC Musculoskeletal Disorders 2010, 11:77
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clinics that mailed questionnaires to eligible participants
[4]. Campbell et al., in their attempt to assess the physical
consequences of IPV with a questionnaire that was
mailed, reported a response rate of only 12 percent [17].
In contrast to the use of mailed questionnaires, written
self-reported surveys such as the questionnaire suggested
in the proposed study design may have less likelihood of
response bias. Use of such questionnaires has resulted in
response rates between 62 percent and 95 percent among
women who are invited into the study personally by
research personnel and then administered the question-
naire if they chose to participate [1,4,18,19].
Inclusion and Exclusion Criteria
All women who present to a recruiting orthopaedic or
trauma clinic will be screened for eligibility. Our inclu-
sion criteria for this observational study are: 1) The
patient presents to the fracture clinic for her own
appointment; 2) The patient is 16 or 18 years of age or
older; 3) The patient is able to read and write well enough
to complete the study questionnaires; 4) The patient is
being seen at the fracture clinic for the treatment of an
orthopaedic injury; and 5) The patient is able to separate
herself from anyone who accompanied her to the fracture
clinic to complete the questionnaire in privacy. Clinical
sites may include patients who are over the age of 16
years in the study if it is permitted by their Research Eth-
ics Board. Some sites may not allow patients under the
age of 18 to participate. Lowering the age requirement to
16, where possible, will improve the generalizability of the
study and will allow us to determine the rates of IPV in a
younger demographic.
The exclusion criteria for this study are: 1) The patient
is considered too ill or injured to participate in the study;
and 2) The patient is cognitively impaired and unable to
participate in the study.
Similar inclusion and exclusion criteria have been used
in other studies that sought women's experience with IPV
[1,3,8,16]. Once a patient is deemed eligible, she will be
invited to participate in the study by a female study coor-
dinator. We will track the number of patients screened
and their reasons for ineligibility.
Primary and Secondary Outcome Measures
To measure the prevalence of IPV, our questionnaire will
ask patients if their intimate partner had abused them
physically, emotionally, or sexually in the past 12 months
and throughout their lifetime. We believe that it is impor-
tant that our study attempt to quantify levels of emotional
and sexual abuse among our intended study sample
because the various forms of IPV - physical, emotional,
and sexual abuse - are concomitant with each other, and
orthopaedic surgeons may serve as a second line of detec-
tion of IPV if victims are undetected in healthcare set-
tings antecedent to their presentation to the orthopaedic
clinic, such as the emergency department. Moreover, we
take the stance that orthopaedic surgeons should be con-
cerned about the holistic care of the individual instead of
only being concerned with what is immediately treatable
in their area of expertise. Therefore, to estimate the over-
all prevalence of IPV, we will combine the positive
answers to the questions on physical, emotional, or sexual
abuse.
We will also ask participants to complete two validated
questionnaires that were designed for rapid assessment of
IPV status in emergency departments, family practice,
and women's health clinics that may be similar to our
intended setting of an orthopaedic fracture clinic. We
selected the Woman Abuse Screening Tool (WAST) and
the Partner Violence Screen (PVS) for their psychometric
properties, reliability, and specificity in identifying part-
ner abuse. Moreover, a study that was published in 2006
reported that 94 percent of women who were adminis-
tered both the PVS and WAST concurrently, as written
questionnaires, considered them "easy" to complete [18].
Both questionnaires are widely used in IPV screening
studies [18,20-26].
We chose to request that both questionnaires be
administered to each participant to ensure that we are
identifying all probable cases of IPV among women who
attend orthopaedic clinics. In addition to the elucidation
of physical abuse, the WAST contains questions that
assess the levels of emotional and sexual abuse that we
also feel are important to ascertain in our study, as men-
tioned previously.
Another research question that will be addressed in the
study is what are patients' previous experiences and per-
ceptions about discussing IPV with health care profes-
sionals. To that end, the questionnaire will also query the
participant about her age, income, education, race/eth-
nicity, marital status, sexual orientation, and length of
relationship. Additionally, participants will be queried
about perceptions and previous experiences with report-
ing IPV in health care settings.
The questionnaire will also ask participants to record
the characteristics of the injury that they are being seen
for in the fracture clinic including: type of injury, how the
injury occurred, locations of injury, and date of injury.
Data Collection
The self-report component of the data collection will
involve a written self-completed questionnaire. This
method of data collection has been shown in a random-
ized trial to provide the least amount of missing data by
the respondent and is generally favored over the use of a
face-to-face interview or computer-based self-completed
questionnaire [18].  BMC Musculoskeletal Disorders 2010, 11:77
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A female study coordinator at each participating clini-
cal site will approach all female patients who present to
the fracture clinic for participation in this study. Due to
the sensitive nature of the study, the informed consent
process and completion of the questionnaire will take
place in a private location by the female study coordina-
tor. A screening form will be completed for all patients
that will document their eligibility and whether they
agree to participate in this study. After providing
informed consent, the female study coordinator will pro-
vide the participant with the questionnaire to complete.
When the participant has completed the questionnaire,
she will place it in a sealed envelope and return it to the
study coordinator. This process is described in Figure 2.
Ethical Considerations
Due to the nature of the research topic, care must be
exercised when recruiting individuals to participate in the
study. Women are often afraid of disclosing that they are
a victim of IPV for fear of retaliation from the offender,
stigmatization by the individuals that she discloses to,
embarrassment, and police involvement [27]. Because of
this fear, key ethical issues addressed in this study are: 1)
requirement for free and informed consent; 2) respect for
privacy and confidentiality; 3) respect for justice and
inclusiveness; 4) minimizing harm; and 5) maximizing
benefit. Each of these items are discussed in greater detail
below.
If an individual agrees to be approached by a study
coordinator, the study coordinator will first ascertain
whether the individual is eligible for participation and ask
the participant if she would be able to accompany the
study coordinator by herself to a private location to par-
ticipate in a women's health survey. At no point during
this initial contact will there be any mention of the words
"abuse" or "violence." If the potential participant is able to
come by herself into the private location, the informed
consent process will be carried out, and the study coordi-
nator will remain in the private location to ensure that the
participant is not interrupted as she completes the ques-
tionnaire.
To maximize the opportunity for free and informed
consent while respecting privacy and confidentiality, the
informed consent process will only take place privately.
Potential participants will not be invited to join the study
if the study coordinator is not able to secure an opportu-
nity when the individual is alone long enough to ade-
quately explain the study and obtain informed consent.
By approaching the potential participant in private, she
also has the opportunity to provide free consent in the
absence of significant others that may affect her decision
to participate. Privacy and confidentiality will further be
secured by assuring that research numbers will be used in
the place of personal identifiers and that no medical per-
sonnel involved in the participant's care will know
whether she participates in the study.
Justice and inclusiveness are respected by including all
individuals who present to the orthopaedic fracture clinic
that are relevant to the research question. Age restric-
tions are in place in light of possible legislative require-
ments within the geographic areas of the recruiting
clinics, and exclusion criteria have been minimized to
only those individuals who have a high likelihood of pro-
viding poor quality data or being unable to properly pro-
vide free and informed consent, given that the
questionnaire is available only in the primary language of
each participating site (i.e. English in Canada and the
United States and Dutch in the Netherlands).
Harm will be minimized by respecting the participant's
privacy and affirming to her that the care she receives is
in no way affected by her decision to participate or not
participate in the study. In addition, Dearwater et al.
noted in their study that as a safety precaution women
were only administered their questionnaire while in the
absence of any friends, family, or medical staff [3]. We
will adopt these criteria for our study as well.
To maximize benefit, individuals who are approached
to participate in the study will be offered information
resources pertaining to IPV and contact information of
local IPV services in the clinic area. Fracture clinic staff
will also be aware of the study and will also be provided
with these materials in the event that the individual
approached would prefer to speak to her care provider(s)
about IPV instead of members of the study team.
Protecting Against Sources of Bias
A bias towards under-reporting IPV is our primary con-
cern. Considerations with respect to confidentiality will
be addressed during data collection to reduce bias when
participants are completing the questionnaire. Partici-
pants will be approached by a female study coordinator,
and the consent process and the completion of the ques-
tionnaire will take place alone in a private location so as
to reduce influence from others. Additionally, partici-
pants will be told that the survey is anonymous and will
be instructed to not discuss the nature of this study with
other participants, so as to increase reporting of IPV, if it
exists, when completing the survey (participants may
answer the questionnaire differently if they knew that
they would be identified as IPV victims or non-IPV vic-
tims by the individual administering the questionnaire).
Questions pertaining to the participant's demographics
should be subject to minimal bias because the questions
are categorical and are not intended to be subjective. An
under-reporting bias is certainly possible; however, if our
study finds an appreciable prevalence of IPV among
respondents, we will have confidence that the likely "true"
estimate is even higher.  BMC Musculoskeletal Disorders 2010, 11:77
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Figure 2 Participant Enrollment Procedures.
Another source of potential bias in this study is that the
questionnaire is self-administered as opposed to inter-
view administered. This may result in some missing and
inconsistent data. Due to the extremely sensitive and pri-
vate information, as well as taking the women's safety into
consideration, we believe that an interview-administered
questionnaire is not appropriate. Due to the sensitive
content of the questionnaire, the study coordinator will
not check it over following completion therefore she will
not be able to ask the patient about missing questions or
inconsistencies.
An inherent limitation of this study which may produce
bias is that non-participants may differ from participants
in terms of demographics and abuse prevalence. Patients
may be less likely to participate if they are a victim of IPV,
thus resulting in a lower IPV prevalence rate. Also, some
patients may decline to participate because they are not
victims of IPV and as such feel that the issue is not rele-
vant to them. Another limitation which may lower the
reported IPV prevalence is that we may miss women who
are severely injured as a result of IPV because we will not
approach women who are taken to the fracture clinic by
Emergency Medical Services. However, we may approach
these patients at subsequent follow-up visits.
Ontario PRAISE Pilot Study
In preparation for the multi-center definitive P.R.A.I.S.E.
study, we successfully completed a pilot study in Ontario,
Canada at two clinical sites (Hamilton Health Sciences -
General Site, Hamilton and St. Michael's Hospital,
Toronto). The purpose of the pilot study was to provide
estimates of patient enrollment, inform study logistics,
and prove feasibility for the definitive study. The patients
from the pilot study will not be included in the larger pro-  BMC Musculoskeletal Disorders 2010, 11:77
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spective study, as we have made multiple changes to the
protocol and questionnaire based on our experience with
the pilot study.
Our preliminary pilot work suggests that women pre-
senting to the fracture clinics are experiencing IPV to
much greater extents than previously recognized by
orthopaedic surgeons. In a sample of 282 women at the
two participating sites, we found that over the past 12
months 8.5% of women were physically abused, 30.5%
were emotionally abused and 3.2% were sexually abused
[15]. One third of women in the pilot study sample had
experienced IPV (including physical, emotional and/or
sexual abuse) in the past 12 months. Our pilot study also
found that 2.5% of women presenting to the fracture clin-
ics with orthopaedic injuries suffered these injuries as a
direct result of IPV. The generalizability of our pilot study
results to all North American, Australian, and European
centers requires confirmation from our proposed larger
study.
Feasibility of the Multicenter Definitive Study
The pilot study helped to inform our enrollment rate as
well as inform the study logistics. We enrolled 204
patients over five months at the site in Hamilton, which
equates to approximately 40 patients per month. St.
Michael's Hospital enrolled 78 patients over 2.5 months,
or approximately 30 patients per month. Therefore we
believe that sites will enroll between 30 and 40 patients
per month and that it will take approximately 10 months
of enrollment at each site to complete the pilot study.
Therefore, it is feasible to complete the definitive multi-
center study within the allotted timeframe.
We also made multiple revisions to the protocol and
questionnaire based on our experience with the pilot
study. We believe these changes will make the question-
naire easier to complete for participants and also enhance
the quality of the data obtained.
Sample Size
According to a recent survey of orthopaedic surgeons in
Canada [7], 87 percent of all respondents believe that the
prevalence of IPV within their practice is less than 1 per-
cent, with almost all of the remaining respondents believ-
ing that the prevalence of IPV in their practice is between
5 percent and 10 percent. Using an estimated IPV preva-
lence of 5 percent within orthopaedic clinics and stan-
dard statistical formulae for estimating sample size of
prevalence studies, we have calculated that a sample size
of 278 women is necessary for our study to provide an
estimate of IPV prevalence with a 95 percent confidence
interval between 2.78 percent and 8.31 percent. If the
point-estimate of IPV prevalence within orthopaedic
clinics is higher than 5 percent, the proportion of the
margin of error relative to the estimated prevalence will
be lower. To be adequately powered within each region or
demographic, each site will therefore recruit 300 partici-
pants. The total sample size for the study will be 3,600
participants across the 12 participating centers.
Data Analysis
Data will be analyzed using SPSS Version 17.0 [SPSS,
Chicago, IL] and will be stratified according to clinical
center, at which point descriptive statistics can be
reported for each site and overall. Dichotomous data will
be reported as number of participants and proportions,
with corresponding confidence intervals to estimate pre-
cision. Continuous data will be presented as means and
medians with standard deviations. We will provide
descriptive statistics describing the patient demographics
and injury characteristics across each clinical site. We will
also report the results of the WAST and PVS across each
clinical site for IPV prevalence in the past 12 months.
These two screening tools will be scored according to the
developers guidelines. Finally, we will report descriptive
statistics, with 95% confidence intervals, across each clin-
i c a l  s i t e  o n  p a t i e n t ' s  p r e v i o u s  e x p e r i e n c e s ,  k n o w l e d g e ,
and perceptions with regards to approaching health care
professionals about IPV. We will use Chi-square tests
(dichotomous variables) or t-tests (continuous data) to
determine if there are differences in IPV prevalence
across different clinical sites and jurisdictions.
Methods Center
The Project Manager at the McMaster University Meth-
ods Center will be responsible for the overall day to day
coordination of the study. The Project Manager will be
responsible for communicating with the clinical sites,
providing the clinical sites with the necessary case report
forms and validating the data. The Project Manager will
also work with the Research Coordinators at the clinical
sites to ensure that the protocol is followed and that 3,600
participants are recruited for this study in the allotted
timeframe.
Participating Centers
The necessity of a multicenter study is twofold. First, as
there are currently no prevalence reports of IPV in
women who attend orthopaedic trauma clinics, a cross-
sectional study will provide the first report of IPV preva-
lence in orthopaedic trauma clinics. Second, the collec-
tion of data from clinics across North America, Europe,
and Australia will enhance the generalizability of our
study. We will include clinical sites from a variety of
trauma populations and settings (i.e. inner city versus
suburban versus rural). Additional centers may be added
to allow for further comparisons of the prevalence of IPV
across different settings and to increase the generalizabil-
ity of the findings.  BMC Musculoskeletal Disorders 2010, 11:77
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Recruitment Rate
For the multi-center definitive P.R.A.I.S.E. study we aim
to recruit 3,600 participants across 12 sites in North
America, Europe, and Australia. The pilot study helped to
inform our enrollment rate proving feasibility of the
definitive trial whereby both clinical sites in the pilot
study enrolled at least 30 patients per month (St.
Michael's Hospital with 30 participants per month and
Hamilton Health Sciences - General Site with 40 partici-
pants per month). Consecutive patients will be recruited
from fracture clinics across North America, Europe, and
Australia and based on the results of our pilot study we
anticipate that each site will be able to enroll 300 patients
within ten months.
Discussion
If the prevalence of IPV among women attending ortho-
paedic clinics is greater than the current perceptions of
orthopaedic surgeons, this study will serve to advocate
for the continued education of medical professionals to
better recognize probable IPV cases and offer existing
services to enhance the care of these patients. This is
especially important because healthcare providers who
receive education on screening and ways to care for IPV
victims detect them more readily [27]. Furthermore, this
study may encourage more open communication
between orthopaedic surgeons and their patients, as two
major barriers to IPV detection are either the patient is
never asked [28] or the healthcare provider is reluctant to
inquire [7,8,16]. A positive study will also inform the
Canadian Orthopaedic Association's position statement
on the role of the orthopaedic surgeon and domestic vio-
lence.
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